TVTX:NASDAQTravere Therapeutics, Inc. Analysis

Travere Therapeutics (TVTX) is riding a strong bullish technical backdrop: the 20‑day SMA (≈45.8) sits above the 50‑day (≈42) and 200‑day (≈32.9) averages, the MACD line remains above its signal, and the RSI of 68 signals continued momentum despite edging toward overbought levels. Support at $41.32 and a nearby resistance ceiling of $52.72 frame the current price of $52.04, while volume is on an upward trend and the 30‑day volatility exceeds 50%, underscoring a highly active market.
Fundamentally, the company posts a forward PE of 10.6 versus an industry average of 24.8, yet a discounted cash‑flow model caps fair value near $10, implying a substantial premium. The balance sheet shows $264 M cash against $328 M debt, and operating margins remain negative, highlighting cash‑burn concerns. Recent material news—an FDA approval lift, a presentation at the Bank of America Global Healthcare Conference, and fresh inducement RSU grants—adds short‑term catalyst fuel, but the high beta (≈1.8) and sector‑specific regulatory risk keep the long‑term outlook cautious.